JP2006508953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006508953A5 JP2006508953A5 JP2004550784A JP2004550784A JP2006508953A5 JP 2006508953 A5 JP2006508953 A5 JP 2006508953A5 JP 2004550784 A JP2004550784 A JP 2004550784A JP 2004550784 A JP2004550784 A JP 2004550784A JP 2006508953 A5 JP2006508953 A5 JP 2006508953A5
- Authority
- JP
- Japan
- Prior art keywords
- prevention
- pancreatic cancer
- synergistic treatment
- pharmaceutically acceptable
- combination
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000002265 prevention Effects 0.000 claims 4
- 230000002195 synergetic effect Effects 0.000 claims 4
- -1 2-chloro-5-methoxyanilino Chemical group 0.000 claims 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 3
- 201000002528 pancreatic cancer Diseases 0.000 claims 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 3
- 229940122924 Src inhibitor Drugs 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 2
- 229960005277 gemcitabine Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- 208000032289 susceptibility to 2 pancreatic cancer Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0226434.9A GB0226434D0 (en) | 2002-11-13 | 2002-11-13 | Combination product |
| PCT/GB2003/004787 WO2004043472A1 (en) | 2002-11-13 | 2003-11-07 | Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006508953A JP2006508953A (ja) | 2006-03-16 |
| JP2006508953A5 true JP2006508953A5 (enExample) | 2006-12-21 |
Family
ID=9947715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550784A Pending JP2006508953A (ja) | 2002-11-13 | 2003-11-07 | 非受容体チロシンキナーゼのＳｒｃファミリーの阻害剤、および、ゲムシタビンの組み合わせ製品 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060142297A1 (enExample) |
| EP (1) | EP1562612B1 (enExample) |
| JP (1) | JP2006508953A (enExample) |
| KR (1) | KR20050074573A (enExample) |
| CN (1) | CN100467027C (enExample) |
| AT (1) | ATE456370T1 (enExample) |
| AU (1) | AU2003279456B2 (enExample) |
| BR (1) | BR0316170A (enExample) |
| CA (1) | CA2504666A1 (enExample) |
| DE (1) | DE60331162D1 (enExample) |
| ES (1) | ES2338109T3 (enExample) |
| GB (1) | GB0226434D0 (enExample) |
| NO (1) | NO20052312L (enExample) |
| NZ (1) | NZ539514A (enExample) |
| WO (1) | WO2004043472A1 (enExample) |
| ZA (1) | ZA200503805B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| GB0223380D0 (en) * | 2002-10-09 | 2002-11-13 | Astrazeneca Ab | Combination therapy |
| RU2350618C2 (ru) | 2002-11-04 | 2009-03-27 | Астразенека Аб | ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ |
| EP1604665B1 (en) | 2003-03-10 | 2011-05-11 | Eisai R&D Management Co., Ltd. | C-kit kinase inhibitor |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| JP4303726B2 (ja) | 2003-11-11 | 2009-07-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ウレア誘導体およびその製造方法 |
| GB0412074D0 (en) | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
| US8969379B2 (en) | 2004-09-17 | 2015-03-03 | Eisai R&D Management Co., Ltd. | Pharmaceutical compositions of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7=methoxy-6-quinolinecarboxide |
| GB0427697D0 (en) * | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| JP4989476B2 (ja) | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| CN104706637A (zh) | 2006-05-18 | 2015-06-17 | 卫材R&D管理有限公司 | 针对甲状腺癌的抗肿瘤剂 |
| JP5368096B2 (ja) | 2006-08-28 | 2013-12-18 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 未分化型胃癌に対する抗腫瘍剤 |
| EP2116246A1 (en) | 2007-01-19 | 2009-11-11 | Eisai R&D Management Co., Ltd. | Composition for treatment of pancreatic cancer |
| WO2008093855A1 (ja) | 2007-01-29 | 2008-08-07 | Eisai R & D Management Co., Ltd. | 未分化型胃癌治療用組成物 |
| CA2704000C (en) | 2007-11-09 | 2016-12-13 | Eisai R&D Management Co., Ltd. | Combination of anti-angiogenic substance and anti-tumor platinum complex |
| CA2771403C (en) | 2009-08-19 | 2015-02-24 | Eisai R&D Management Co. Ltd. | Quinoline derivative-containing pharmaceutical composition |
| CN102958523B (zh) | 2010-06-25 | 2014-11-19 | 卫材R&D管理有限公司 | 使用具有激酶抑制作用的组合的抗肿瘤剂 |
| AU2012246490B2 (en) | 2011-04-18 | 2016-08-04 | Eisai R&D Management Co., Ltd. | Therapeutic agent for tumor |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
| WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| CA2912219C (en) | 2013-05-14 | 2021-11-16 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP3187491A4 (en) | 2014-08-28 | 2018-08-01 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
| US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
| KR20240064733A (ko) | 2015-03-04 | 2024-05-13 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| US20170022576A1 (en) | 2015-03-18 | 2017-01-26 | The Regents Of The University Of California | Compositions and methods for identifying anti-cancer, anti-metastatic and anti-stress agents |
| CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
| CN108135894B (zh) | 2015-08-20 | 2021-02-19 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| CN110072528B (zh) | 2017-02-08 | 2022-04-26 | 卫材R&D管理有限公司 | 治疗肿瘤的药物组合物 |
| WO2018212202A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9603408D0 (sv) * | 1996-09-18 | 1996-09-18 | Astra Ab | Medical use |
| PT1115391E (pt) * | 1998-09-25 | 2003-02-28 | Warner Lambert Co | Quimioterapia do cancro com acetildinalina em combinacao com gemcitabina capecitabina ou cisplatina |
| EP1206265B1 (en) * | 1999-06-30 | 2003-11-12 | Merck & Co., Inc. | Src kinase inhibitor compounds |
| US6503914B1 (en) * | 2000-10-23 | 2003-01-07 | Board Of Regents, The University Of Texas System | Thienopyrimidine-based inhibitors of the Src family |
| GB0101599D0 (en) * | 2001-01-22 | 2001-03-07 | Novartis Ag | Organic compounds |
| GB0310401D0 (en) * | 2003-05-07 | 2003-06-11 | Astrazeneca Ab | Therapeutic agent |
| GB0412074D0 (en) * | 2004-05-29 | 2004-06-30 | Astrazeneca Ab | Combination product |
-
2002
- 2002-11-13 GB GBGB0226434.9A patent/GB0226434D0/en not_active Ceased
-
2003
- 2003-11-07 JP JP2004550784A patent/JP2006508953A/ja active Pending
- 2003-11-07 NZ NZ539514A patent/NZ539514A/en unknown
- 2003-11-07 KR KR1020057008291A patent/KR20050074573A/ko not_active Withdrawn
- 2003-11-07 CA CA002504666A patent/CA2504666A1/en not_active Abandoned
- 2003-11-07 AT AT03772404T patent/ATE456370T1/de not_active IP Right Cessation
- 2003-11-07 AU AU2003279456A patent/AU2003279456B2/en not_active Ceased
- 2003-11-07 ES ES03772404T patent/ES2338109T3/es not_active Expired - Lifetime
- 2003-11-07 DE DE60331162T patent/DE60331162D1/de not_active Expired - Lifetime
- 2003-11-07 WO PCT/GB2003/004787 patent/WO2004043472A1/en not_active Ceased
- 2003-11-07 BR BR0316170-6A patent/BR0316170A/pt not_active IP Right Cessation
- 2003-11-07 CN CNB2003801031384A patent/CN100467027C/zh not_active Expired - Fee Related
- 2003-11-07 EP EP03772404A patent/EP1562612B1/en not_active Expired - Lifetime
- 2003-11-07 US US10/534,721 patent/US20060142297A1/en not_active Abandoned
-
2005
- 2005-05-11 NO NO20052312A patent/NO20052312L/no not_active Application Discontinuation
- 2005-05-11 ZA ZA200503805A patent/ZA200503805B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2020026I1 (no) | Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet | |
| JP2007536311A5 (enExample) | ||
| TW200505924A (en) | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| WO2005005414A3 (en) | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | |
| NO20076613L (no) | Farmasoytiske formuleringer og anvendelse derav | |
| DE602004017194D1 (de) | Pyridylpyrrol-derivate als wirksame kinase-hemmer | |
| GEP20105025B (en) | Pharmaceutical compositions for treatent of atherosclerosis and related conditions and use thereof for treatment of these diseases | |
| WO2005065646A3 (en) | Novel drug compositions and dosage forms | |
| PH12013502277A1 (en) | Modified release of 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-n-5-(4 methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl] benzamide solubilized using organic acids | |
| DK2324008T3 (da) | Diarylpyrazol som protein kinase inhibitorer | |
| NO20090443L (no) | 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater | |
| EA200900264A1 (ru) | Композиции флибансерина и способ их приготовления | |
| MX2008013836A (es) | Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos. | |
| MX2009006613A (es) | Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa. | |
| UY27462A1 (es) | Derivados de quinolina | |
| WO2005014572A8 (en) | Pyrimidylpyrrole derivatives active as kinase inhibitors | |
| EA200971087A1 (ru) | Фармацевтические композиции и способ лечения острой мании | |
| JP2018090566A5 (enExample) | ||
| NO20073403L (no) | Anvendelse av atazanavir til forbedring av farmakokinetikken til legemidler metabolisert av UGT1A1 | |
| TW200624431A (en) | Phthalazinone derivatives, their manufacture and use as pharmaceutical agents | |
| EP4442321A3 (en) | Methods of treating sjögren's syndrome using a bruton's tyrosine kinase inhibitor | |
| NZ594369A (en) | Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases | |
| UA102219C2 (ru) | Замещенные пиразолохиназолиновые производные, способ их получения и их применения как ингибиторов киназы | |
| JP2009518415A5 (enExample) | ||
| WO2007057221A3 (en) | Pharmaceutical compositions for the treatment of inflammatory and obstructive airways diseases |